医学临床研究
  2025年6月12日 星期四           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2018, Vol. 35 Issue (11): 2121-2123    DOI: 10.3969/j.issn.1671-7171.2018.11.014
  论 著 本期目录 | 过刊浏览 | 高级检索 |
阿奇霉素联合孟鲁司特治疗儿童咳嗽变异性哮喘伴MP感染的疗效
张晓红, 李玲梅
攀枝花市攀钢集团总医院儿科,四川 攀枝花 617023
Clinical Observation of Azithromycin Combined with Montelukast in the Treatment of Cough Variant Asthma with Mycoplasma Pneumoniae Infection in Children
ZHANG Xiao-hong, LI Ling-mei
Department of Pediatrics; Panzhihua General Hospital of Panzhihua Iron and Steel Group Panzhihua, Sichuan, 617023
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨阿奇霉素联合孟鲁司特治疗儿童咳嗽变异性哮喘(CVA)伴肺炎支原体感染(MP)感染的疗效。【方法】120例MP感染的CVA患儿,随机分为两组,各60例,对照组采用予以阿奇霉素,观察组在对照组治疗基础上加用孟鲁司特,均治疗7 d,疗程结束后观察两组临床疗效及不良反应,比较两组治疗前后血清炎症因子及免疫球蛋白水平。【结果】对照组总有效率为83.3%(50/60),显著低于观察组的95.0%(57/60)(P<0.05);两组嗜酸性细胞阳离子(ECP)、白介素-5(IL-5)、金属基质蛋白酶-9(MMP-9)、金属基质蛋白酶抑制剂-1(TIMP-1)水平和IgE、嗜酸性粒细胞(EOS)较治疗前显著下降(P<0.05),且治疗后观察组各指标均显著低于对照组(P<0.05);对照组咳嗽消失时间、喘息消失时间、体温恢复正常时间均显著高于观察组(P<0.05);对照组不良反应总发生率为11.67%(7/60),与观察组8.33%(5/60)比较差异无显著性(P>0.05)。【结论】阿奇霉素联合孟鲁司特治疗儿童MP感染的CVA疗效显著,可降低气道超敏反应,减轻气道炎症反应,促进患儿康复。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
张晓红
李玲梅
关键词 哮喘/并发症肺炎, 支原体/并发症白三烯拮抗剂/治疗应用大环内酯类/治疗应用    
Abstract:【Objective】To investigate the efficacy of azithromycin combined with montelukast in the treatment of children of cough variant asthma (CVA) with Mycoplasma pneumonia (MP) infection . 【Methods】A total of 120 cases of children diagnosed with CVA and MP infection were selected for the study and divided into two groups with 60 cases in each group according to the random table method. The control group (B group) was treated with azithromycin, while the observation group (A group) was additionally given montelukast on the basis of azithromycin treatment. The treatments in both groups lasted 7 days. After the course of treatment, the clinical efficacies of the two groups were observed and the serum levels of inflammatory factors and immunoglobulins were compared between the two groups before and after treatment. Adverse reactions were recorded as well. 【Results】The total effective rate was 83.3% in B group, which was significantly lower than that in A group with 95.0% (P<0.05). The levels of ECP, IL-5, MMP-9,TIMP-1 and IgE , and EOS in the two groups were significantly lower than those before treatment (P<0.05) and the indexes in A group after treatment were significantly lower than those in B group (P<0.05). The cough disappearance time, wheezing disappearance time, temperature recovery time in B group were significantly better than those in A group. The overall incidence rate of adverse reactions was 11.67%(7/60)in B group, which was not significantly different from that in A group with 8.33%( 5/60) (P>0.05). 【Conclusion】Azithromycin combined with montelukast can have a significant clinical efficacy, can reduce airway hypersensitivity and airway inflammation, and promote rehabilitation of children in the treatment of CVA with MP infection.
Key wordsAsthma/CO    Pneumonia, Mycoplasma/CO    Leukotriene Antagonists/TU    Macrolides/TU
收稿日期: 2016-12-23     
PACS:  R256.12  
引用本文:   
张晓红, 李玲梅. 阿奇霉素联合孟鲁司特治疗儿童咳嗽变异性哮喘伴MP感染的疗效[J]. 医学临床研究, 2018, 35(11): 2121-2123.
ZHANG Xiao-hong, LI Ling-mei. Clinical Observation of Azithromycin Combined with Montelukast in the Treatment of Cough Variant Asthma with Mycoplasma Pneumoniae Infection in Children. JOURNAL OF CLINICAL RESEARCH, 2018, 35(11): 2121-2123.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2018.11.014     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2018/V35/I11/2121
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn